Asia Pacific Myasthenia Gravis Treatment Market Size & Outlook
Asia Pacific myasthenia gravis treatment market, 2018-2032 (US$M)
Related Markets
Asia Pacific myasthenia gravis treatment market highlights
- The Asia Pacific myasthenia gravis treatment market generated a revenue of USD 212.8 million in 2021.
- The market is expected to grow at a CAGR of 11.3% from 2022 to 2032.
- In terms of segment, monoclonal antibodies was the largest revenue generating treatment type in 2021.
- Monoclonal Antibodies is the most lucrative treatment type segment registering the fastest growth during the forecast period.
- Country-wise, Singapore is expected to register the highest CAGR from 2022 to 2032.
Asia Pacific data book summary
| Market revenue in 2021 | USD 212.8 million |
| Market revenue in 2032 | USD 691.8 million |
| Growth rate | 11.3% (CAGR from 2021 to 2032) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2032 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
| Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 12.1% of the global myasthenia gravis treatment market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2032.
- MEA is the fastest growing regional market and is projected to reach USD 79.4 million by 2032.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia Gravis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific myasthenia gravis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 52.58% in 2021. Horizon Databook has segmented the Asia Pacific myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
The Asia Pacific myasthenia gravis treatment market is expected to grow at the fastest rate owing to presence of a large target population in countries, such as India, China, Japan, and South Korea. In addition, growing adoption of innovative MG diagnosis techniques & treatment therapies in these countries is one of the key factors driving market growth.
Moreover, presence of local drug manufacturers and entry of leading companies in Asia Pacific countries through strategic collaborations are among factors further expected to support regional growth.
Reasons to subscribe to Asia Pacific myasthenia gravis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific myasthenia gravis treatment market databook
-
Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific myasthenia gravis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific myasthenia gravis treatment market size, by country, 2018-2032 (US$M)
Asia Pacific Myasthenia Gravis Treatment Market Outlook Share, 2021 & 2032 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
